Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector, emphasizing the potential for investment in bottom assets within the industry [5]. Core Insights - The report highlights the ongoing opportunities in the pharmaceutical sector, particularly in areas such as AI in medicine and innovative drug developments, while noting the recent market performance where the pharmaceutical sector outperformed the broader market [11][26]. - It emphasizes the importance of monitoring key milestones and data updates from major conferences in 2026, such as AACR and ASCO, which could significantly impact investment decisions [11]. Summary by Sections Market Performance - The pharmaceutical sector has shown a return of 3.28% since the beginning of 2026, outperforming the Shanghai Composite Index by 2.99 percentage points [26]. - Recent weekly performance indicates a slight increase in the pharmaceutical sector by 0.14%, while the broader market declined by 1.33% [11][26]. Investment Opportunities - The report identifies several key areas for investment, including: - IO plus strategies involving VEGF dual antibodies, which are gaining traction in clinical trials [12]. - ADC (Antibody-Drug Conjugates) with a focus on large indications and new indications that could enhance overseas mapping [14]. - The development of new RAS inhibitors and their potential in treating various cancers, highlighting companies like 加科思 and 劲方生物 [15]. - The commercial potential of CDK4/6 inhibitors in HR+ breast cancer, particularly as patents expire [16]. Key Companies and Recommendations - The report recommends several companies for investment, including: - 药明生物, 泰格医药, 先声药业, 康弘药业, 普洛药业, 美好医疗, 迪安诊断, 和铂医药-B, 药石科技, and 天宇股份, all of which are expected to perform well in the current market environment [8][19]. - It notes that the pharmaceutical sector's current valuation is 22.8 times PE based on 2026 earnings forecasts, indicating a premium over the broader A-share market [30]. Clinical Developments - The report discusses various clinical trials and their implications, such as: - The anticipated data readouts for several ADCs and dual antibodies in 2026, which could significantly influence market dynamics [17][20]. - The ongoing advancements in small nucleic acids and their expected commercialization, which could lead to substantial market growth [19][23]. Regulatory Environment - The report highlights the regulatory landscape, noting that the National Medical Insurance Administration will intensify oversight in 2026, which may impact pharmaceutical companies [22]. Overall Sector Outlook - The report maintains a positive outlook on the pharmaceutical sector, suggesting that despite recent market fluctuations, there are significant opportunities for growth and investment, particularly in innovative therapies and technologies [11][19].

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical sector [5] Core Insights - The pharmaceutical sector is experiencing a rebound in bottom assets, particularly in traditional Chinese medicine, medical services, and pharmacies, driven by market rotation and price increase expectations in raw materials [7][11] - The report emphasizes the importance of focusing on bottom assets that are expected to see turning points and well-adjusted innovative drug sectors, with a positive outlook on growth directions representing the future of the pharmaceutical industry [11] - Key themes include continuous attention to pharmaceutical and medical AI+, as well as significant data updates expected from major conferences in 2026 [11] Summary by Sections Market Dynamics - The pharmaceutical sector has outperformed the broader market, with a return of 3.28% compared to the Shanghai Composite's 0.29% since the beginning of 2026 [26] - The report notes that the pharmaceutical sector's valuation is currently at 22.8 times PE, with a premium of 11.7% over the overall A-share market [30] Key Company Performance - Recommended stocks for February include WuXi Biologics, Tigermed, and others, with a focus on companies that have shown significant pipeline progress or business development expectations [8][36] - The report highlights the performance of companies like Guangsheng Tang and Nuo Cheng Jian Hua, which have made notable advancements in their core pipelines [36] Industry Trends - The report discusses the trend of combining IO plus therapies and the development of new targets in the dual antibody space, indicating a growing trend in clinical applications [12][14] - Attention is drawn to the ADC (Antibody-Drug Conjugate) sector, particularly large indication FIC (First-in-Class) products and the potential for new indications to enhance overseas mapping [14][17] - The report also highlights the evolving landscape in blood cancers, with new therapies showing promise in previously underserved areas [20]

Core Viewpoint - Tianyu Co., Ltd. announced that its wholly-owned subsidiary, Zhejiang Norde Pharmaceutical Co., Ltd., has received the drug registration certificate for Canagliflozin from the National Medical Products Administration [1] Group 1: Product Approval - The drug Canagliflozin can be used in conjunction with Metformin to improve blood sugar control in adult patients with type 2 diabetes when Metformin alone is insufficient [1] - Canagliflozin can also be used in combination with Metformin and Sulfonylureas to enhance blood sugar control in adult patients with type 2 diabetes when the combination of these medications is not effective [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received the drug registration certificate for Canagliflozin Tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Approval - The product is indicated for use in adult patients with type 2 diabetes to improve blood sugar control when used in combination with Metformin [1] - It can also be used in conjunction with Metformin and sulfonylureas when blood sugar control is inadequate with these medications alone [1] - The product is not recommended for improving blood sugar control in patients with type 1 diabetes [1]

Core Viewpoint - Tianyu Co., Ltd. (300702.SZ) announced that its wholly-owned subsidiary, Zhejiang Nuode Pharmaceutical Co., Ltd., has received the drug registration certificate for Canagliflozin Tablets from the National Medical Products Administration (NMPA) [1] Group 1: Product Approval - The product is indicated for use in adult patients with type 2 diabetes to improve blood sugar control when used in combination with Metformin [1] - It can also be used in conjunction with Metformin and sulfonylureas when blood sugar control is inadequate with these medications alone [1] - The product is not recommended for improving blood sugar control in patients with type 1 diabetes [1]

证券代码：300702 证券简称：天宇股份 公告编号：2026-008 浙江天宇药业股份有限公司 关于全资子公司药品获得批准的公告 本公司董事会及全体董事保证本公告内容不存在虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 浙江天宇药业股份有限公司（以下简称"公司"）全资子公司浙江诺得药业 有限公司（以下简称"诺得药业"）于近日收到国家药品监督管理局（以下简称 "国家药监局"）核准签发的关于卡格列净片的《药品注册证书》。现将相关情 况公告如下： 一、药品情况 | 药品名称 | 卡格列净片 | | | | | | --- | --- | --- | --- | --- | --- | | 英文名 | Canagliflozin | | | Tablets | | | 剂型 | 片剂 | | | | | | 规格 | 300mg（按 | | | C24H25FO5S | 计） | | 是否处方药 | 是 | | | | | | 申请事项 | 药品注册（境内生产） | | | | | | 注册分类 | 化学药品 4 | 类 | | | | | 药品批准文号 | 国药准字 | ...

Core Viewpoint - Tianyu Co., Ltd. expects a significant year-on-year increase in net profit attributable to shareholders for the full year of 2025, indicating a stable operational foundation despite challenges in the fourth quarter [2] Group 1: Financial Performance - The company reported a decline in gross profit margin in the fourth quarter due to changes in product sales structure, increased costs, and asset impairment provisions [2] - Expenses have increased, contributing to a reduction in overall profit for the fourth quarter compared to the previous periods [2] Group 2: Future Outlook - The company advises stakeholders to refer to the upcoming 2025 Annual Report for detailed financial disclosures and performance metrics [2]

Group 1 - The company stated that it strictly complies with regulatory requirements for information disclosure and currently has no significant information that should be disclosed but has not been [2] - The company will continue to optimize its market value management while adhering to relevant laws and regulations regarding information disclosure [2] - If there are any related plans in the future, the company will fulfill its information disclosure obligations in a timely manner as per regulations [2]

Group 1 - The core viewpoint of the article highlights that Tianyu Co., Ltd. has officially launched its "annual production of 20,000 tons of high-purity solvent project," which has effectively improved capacity utilization [2] - The company continues to solidify its leading position in the raw material drug market for sartans, with significant results from its "raw materials + formulations" integrated strategy, leading to growth in both raw material drug revenue and formulation product revenue [2] - Several product varieties have obtained CEP certification or are in the process of FDA certification, with revenue from certified products expected to gradually materialize as the global market expands [2]

Group 1 - The core viewpoint of the article is that Tianyu Co., Ltd. is currently maintaining stable operational performance and is committed to creating reasonable returns for investors through a scientifically formulated dividend plan based on its 2025 annual performance and future development plans [2] Group 2 - The company has responded to investor inquiries on its interactive platform, indicating confidence in its business operations [2] - Tianyu Co., Ltd. aims to develop a dividend scheme that aligns with its overall business strategy and performance outlook [2]